La cadena de opciones muestra datos clave de las opciones de acciones de Aclaris Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aclaris Therapeutics..

Aclaris Therapeutics (NASDAQ:ACRS) Bolsa, Cadena de Opciones

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

Biotech

Earnings

News

Guidance

Health Care

General

ACRS

Aclaris Had Aggregate Cash, Cash Equivalents And Marketable Securities Of $173.4M As Of September 30, Which Is Expected To Provide Cash Runway Into 2028

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $0.02 by 650 percent. This is a 73.17 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $4.35 million which missed the analyst consensus estimate of $7.12 million by 38.95 percent. This is a 53.18 percent decrease over sales of $9.28 million the same period last year.

Aclaris Therapeutics Q3 2024 GAAP EPS $(0.11) Misses $0.02 Estimate, Sales $4.35M Miss $7.12M Estimate

<h3>Gainers</h3>
<ul>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock increased by 128.3% to $12.1 during Monday's pre-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock moved upwards by 93.43% to $1.12. The market value of their outstanding shares is at $6.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares rose 30.47% to $6.38. The market value of their outstanding shares is at $391.5 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock increased by 21.06% to $5.69. The company's market cap stands at $592.7 million. </li>
<li>PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) stock moved upwards by 14.87% to $79.0. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock rose 14.26% to $16.5. The company's market cap stands at $17.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 16.9% to $26.31 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. The company's, Q3 earnings came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares declined by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) stock declined by 8.29% to $1.55. The company's market cap stands at $110.5 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 7.94% to $0.37. The company's market cap stands at $26.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares decreased by 7.92% to $0.44. The company's market cap stands at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AVTX

EVOK

GLUE

HCTI

MNDR

MNPR

MRNS

PRCT

RVNC

XAIR

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 93.4% to $1.12 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 71.53% to $9.09. The market value of their outstanding shares is at $6.6 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares moved upwards by 32.1% to $6.46. The market value of their outstanding shares is at $396.4 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares moved upwards by 22.27% to $1.18. The company's market cap stands at $18.9 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock rose 21.04% to $5.69. The company's market cap stands at $592.6 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 15.5% to $1.49. The market value of their outstanding shares is at $22.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock declined by 17.0% to $26.29 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 9.84% to $0.32. The company's market cap stands at $4.7 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares declined by 8.88% to $1.54. The market value of their outstanding shares is at $109.8 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock decreased by 8.06% to $0.44. The market value of their outstanding shares is at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENSC

MIRA

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares moved upwards by 62.3% to $0.94 during Friday's after-market session. The company's market cap stands at $5.3 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares rose 23.25% to $1.59. The market value of their outstanding shares is at $23.5 million. </li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) shares rose 22.54% to $3.37. The market value of their outstanding shares is at $22.4 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 16.05% to $5.35. The market value of their outstanding shares is at $224.6 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 15.24% to $0.47. The market value of their outstanding shares is at $75.7 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock rose 9.52% to $1.38. The market value of their outstanding shares is at $46.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares declined by 9.5% to $1.53 during Friday's after-market session. The market value of their outstanding shares is at $109.1 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock declined by 6.95% to $0.37. The company's market cap stands at $26.7 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock decreased by 6.92% to $0.11. The company's market cap stands at $3.0 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 6.92% to $1.73. The market value of their outstanding shares is at $3.2 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock fell 6.69% to $5.86. The market value of their outstanding shares is at $400.7 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 6.44% to $0.46. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMPS

HSDT

HURA

MEIP

NUWE

OKYO

PIII

Qualigen Therapeutics, Inc. - Common Stock

QLGN

12 Health Care Stocks Moving In Friday's After-Market Session

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Neutral.

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Aclaris Therapeutics

The Phase 2a trial is an open-label study to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 administered over 12 weeks in patients with moderate to severe atopic dermatitis. Aclaris&#39; planned enrollment for this trial is approximately 15 subjects, and the trial will be conducted in the United States. The primary endpoints are safety-related parameters. Secondary endpoints include Eczema Area and Severity Index (EASI) response measures, including EASI-50, EASI-75, and EASI-90, Validated Investigator Global Assessment (vIGA) response, body surface area (BSA)&nbsp;response and other pertinent efficacy related measures. Aclaris expects topline data from this trial in the first half of 2025

Aclaris Therapeutics Doses First Patient In Phase 2a Trial Of ATI-2138 For Moderate To Severe Atopic Dermatitis

Aclaris' Cash, Cash Equivalents And Marketable Securities Of $149.9M As Of June 30, 2024 And $26.5M From Sale Of Olumiant Royalties And Milestones Will Be Sufficient To Fund Its Operations Into 2028

Aclaris Therapeutics Q2 2024 GAAP EPS $(0.15) Beats $(0.20) Estimate, Sales $2.766M Beat $1.818M Estimate

The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">BranchOut Food</h3>
<ul>
<li>The Trade: BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) Director Byron Riche Jones <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 41,755 shares at</a> an average price of $0.99. To acquire these shares, it cost around $41,337.</li>
<li>What's Happening: On June 26, Branchout Food announced the pricing of its $1.4 million underwritten public offering of 1.75 million shares of common stock at $0.80 per share.</li>
<li>What BranchOut Food Does: Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders.</li>
</ul>
<h3 class="wp-block-heading">Innovative Food Holdings</h3>
<ul>
<li>The Trade: Innovative Food Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IVFH#OTC">IVFH</a>) Director Denver Johnson Smith <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 350,000 shares at</a> an average price of $1.20. To acquire these shares, it cost around $420,000.</li>
<li>What's Happening: On May 14, the company said revenues in the first quarter fell 5.7% to $15.7 million.</li>
<li>What Innovative Food Holdings Does: Innovative Food Holdings Inc through its subsidiaries is engaged in the distribution of perishables and specialty food products.</li>
</ul>
<h3 class="wp-block-heading">Crown Equity Holdings</h3>
<ul>
<li>The Trade: Crown Equity Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRWE#OTC">CRWE</a>) Marketing/Merger/Acq. Officer Jamie Hadfield <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares</a> at an average price of $0.25. The insider spent around $1,250 to buy those shares. </li>
<li>What's Happening: On June 14, Crown Equity named Ahmad Moradi as the new Chairman of the Board and Chief Strategic &amp; Science Officer.</li>
<li>What Crown Equity Holdings Does: Crown Equity Holdings Inc offers services to companies seeking to become public entities in the United States.</li>
</ul>
<h3 class="wp-block-heading">Aclaris Therapeutics</h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">acquired a total of 154,722 shares</a> at an average price of $1.31. The insider spent around $201,808 to buy those shares.</li>
<li>What's Happening: On July 16, Aclaris Therapeutics announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881526/wall-streets-most-accurate-analysts-say-hold-these-3-utilities-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields</a></li>
</ul>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

CRWE

IVFH

Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying

WIIM

Aclaris Therapeutics shares are trading higher after the company announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.

- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone -

Asset Sales

Aclaris Therapeutics Sells OLUMIANT Royalties And Milestones To OMERS Life Sciences For Up To $31.5M

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adma Biologics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) one of those stocks right now? By taking a look at the stock&#39;s year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adma Biologics is one of 1026 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ADMA&#39;s full-year earnings has moved 18% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ADMA has returned 157.5% so far this year. In comparison, Medical companies have returned an average of 4.4%. As we can see, Adma Biologics is performing better than its sector in the calendar year.
Aclaris Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 21%.
For Aclaris Therapeutics, the consensus EPS estimate for the current year has increased 20.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, a group that includes 500 individual stocks and currently sits at #73 in the Zacks Industry Rank. Stocks in this group have lost about 5.3% so far this year, so ADMA is performing better this group in terms of year-to-date returns.
On the other hand, Aclaris Therapeutics belongs to the Medical - Drugs industry. This 181-stock industry is currently ranked #147. The industry has moved -7.4% year to date.
Investors interested in the Medical sector may want to keep a close eye on Adma Biologics and Aclaris Therapeutics as they attempt to continue their solid performance.
<a href="https://www.zacks.com/stock/news/2298444/is-adma-biologics-adma-stock-outpacing-its-medical-peers-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-2298444">To read this article on Zacks.com click here.</a>

ADMA

Is ADMA Biologics Stock Outpacing Its Medical Peers This Year?

The Dow Jones index closed higher by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Aclaris Therapeutics</h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 352,397 shares</a> at an average price of $1.15. To acquire these shares, it cost around $405,894.</li>
<li>What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>
<h3 class="wp-block-heading">RENN Fund</h3>
<ul>
<li>The Trade: RENN Fund, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCG#NYSE">RCG</a>) President and CEO Murray Stahl <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 184 shares at</a> an average price of $1.74. To acquire these shares, it cost around $320.</li>
<li>What's Happening: RENN Fund shares rose around 5% over the past month.</li>
<li>What RENN Fund Does: RENN Fund Inc is active in the financial services domain.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39646161/top-3-financial-stocks-youll-regret-missing-in-q3">Top 3 Financial Stocks You&#8217;ll Regret Missing In Q3</a>

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Aclaris Therapeutics</h3>
<ul>
<li>The Trade: Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) 10% owner Braden Michael Leonard <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 1,611,200 shares</a> at an average price of $1.11. To acquire these shares, it cost around $1.78 million.</li>
<li>What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.</li>
<li>What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.</li>
</ul>
<h3 class="wp-block-heading">Zomedica</h3>
<ul>
<li>The Trade: Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) Vice President of Sales Russell Kevin Klass <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 299,993 shares at</a> an average price of $0.16. To acquire these shares, it cost around $46,529.</li>
<li>What's Happening: On May 15, Zomedica announced the launch of Over-the-Air software and firmware update capability for its TRUFORMA point-of-care diagnostic platform.</li>
<li>What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.</li>
</ul>
<h3 class="wp-block-heading">Perspective Therapeutics</h3>
<ul>
<li>The Trade: Perspective Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>) CEO Johan M. Spoor <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 100,000 </a>at an average price of $1.17. The insider spent around $117,430 to buy those shares. </li>
<li>What's Happening: On June 11, Perspective Therapeutics announced a 1-for-10 reverse stock split.</li>
<li>What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39311150/top-3-tech-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Tech Stocks That May Fall Off A Cliff This Month</a>

CATX

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 9.75% to $2.25. The market value of their outstanding shares is at $3.2 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock moved upwards by 6.89% to $0.93. The market value of their outstanding shares is at $1.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 6.4% to $1.33. The company's market cap stands at $5.6 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares rose 5.4% to $1.17. The market value of their outstanding shares is at $83.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 4.98% to $0.56. The market value of their outstanding shares is at $39.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock fell 24.4% to $1.21 during Friday's after-market session. The market value of their outstanding shares is at $49.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 14.04% to $0.84. The market value of their outstanding shares is at $14.7 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares decreased by 9.1% to $1.8. The company's market cap stands at $2.1 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 7.75% to $0.29. The market value of their outstanding shares is at $3.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 7.4% to $2.13. The company's market cap stands at $50.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock decreased by 7.18% to $0.29. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

BCLI

CYCC

DHAI

ISPC

LSDI

LUCY

ONMD

STSS

SXTP

WORX

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.29) by 17.24 percent. This is a 42.86 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $1.37 million by 75.04 percent. This is a 5.14 percent decrease over sales of $2.53 million the same period last year.

Earnings Beats

Aclaris Therapeutics Q1 EPS $(0.24) Beats $(0.29) Estimate, Sales $2.40M Beat $1.37M Estimate

BioCryst Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcrx#NASDAQ">BCRX</a>) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 26.09%. A quarter ago, it was expected that this drugmaker would post a loss of $0.24 per share when it actually produced a loss of $0.28, delivering a surprise of -16.67%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
BioCryst, which belongs to the Zacks Medical - Drugs industry, posted revenues of $92.76 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 8.37%. This compares to year-ago revenues of $68.78 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
BioCryst shares have lost about 25.7% since the beginning of the year versus the S&amp;P 500&#39;s gain of 7.5%.
What&#39;s Next for BioCryst?
While BioCryst has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for BioCryst: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $96.97 million in revenues for the coming quarter and -$0.69 on $397.95 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Aclaris Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>), is yet to report results for the quarter ended March 2024. The results are expected to be released on May 7.
This specialty pharmaceutical company is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of +33.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Aclaris Therapeutics&#39; revenues are expected to be $1.99 million, down 21.4% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2268441/biocryst-pharmaceuticals-bcrx-reports-q1-loss-tops-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2268441">To read this article on Zacks.com click here.</a>

Earnings Misses

Small Cap

BCRX

BioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue Estimates

Leerink Partners analyst Thomas Smith maintained a Hold rating on Aclaris Therapeutics (ACRS – Research Report) yesterday and set a price target of...

Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Aclaris Therapeutics (ACRS – Research Report). The compa...

H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Aclaris Therapeutics (ACRS – Research Report) today. The company's shares closed ...

Aclaris Therapeutics (ACRS) Gets a Hold from H.C. Wainwright

BTIG analyst Julian Harrison has maintained their neutral stance on ACRS stock, giving a Hold rating yesterday. Julian Harrison has given his Hold ...

Aclaris Therapeutics' ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Aclaris Therapeutics GAAP EPS of -$0.11 misses by $0.05, revenue of $4.35M misses by $7.5M

Aclaris Therapeutics Inc. ( ($ACRS) ) has released its Q3 earnings. Here is a breakdown of the information Aclaris Therapeutics Inc. presented to i...

Aclaris Therapeutics Reports Positive Q3 2024 Milestones

In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus maintained a Hold rating on Aclaris Therapeutics (ACRS – Research Report), w...

Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aclaris Therapeutics (ACRS – Research Report), McK...

Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)

Analyst Thomas Smith of Leerink Partners maintained a Hold rating on Aclaris Therapeutics (ACRS – Research Report), with a price target of $2.00. T...

Aclaris Therapeutics: Hold Rating Amid Mixed Trial Outcomes and Strategic Uncertainties

EHAB

ELAB

ITRM

Opinion

Press Releases

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Comments

Aclaris Therapeutics

Aclaris Therapeutics (ACRS) Opciones

Aclaris Therapeutics (NASDAQ:ACRS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL